Scholarlink

Background <p>Combining CDK 4/6 inhibitors with endocrine therapy (ET) extends progression-free survival (PFS) and overall survival (OS) in hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2) negative metastatic breast cancer. We aimed to explore the relationship between metabolic tumor volume (MTV), total lesion glycolysis (TLG), and PFS/OS in these patients.</p> Methods <p>MTV and TLG were measured from baseline 18&#xa0;F-fluorodeoxyglucose (18-FDG) positron emission tomography/computed tomography (PET/CT) of 87&#xa0;HR-positive/HER2-negative metastatic breast cancer patients and their effects on survival were analyzed using Kaplan-Meier methods.</p> Results <p>The median OS was 42.0 months for patients with MTV &lt; 121.7&#xa0;cm³ and 24.6 months with ≥ 121.7 cm<sup>3</sup> (<i>p</i> = 0.001). The median OS was 40.3 months for patients with TLG &lt; 732.4&#xa0;g and 24.6 months with ≥ 732.4&#xa0;g (<i>p</i> = 0.006). The median OS for patients with an ECOG score of 0 was 53.6 months, while for those with an ECOG score of 1–2, it was 26.4 months (<i>p</i> = 0.005). Age ≥ 60 years (HR = 5.11, <i>p</i> = 0.002) and ECOG score &gt; 0 (HR = 3.38, <i>p</i> = 0.011) are independent predictors of PFS.</p> Conclusions <p>Baseline 18&#xa0;F-FDG PET/CT may provide prognostic insights in HR+/HER2- metastatic breast cancer. High MTV and TLG are associated with poorer OS in univariate analyses but not in multivariable analyses. ECOG score &gt; 0 and age ≥ 60 years are independent predictors of PFS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Relationship between overall survival and progression-free survival with 18 F-FDG PET/CT metabolic parameters in metastatic breast cancer patients treated with CDK 4/6 inhibitors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Ogün Bülbül,
  • Esra Aydin,
  • Demet Nak

摘要

Background

Combining CDK 4/6 inhibitors with endocrine therapy (ET) extends progression-free survival (PFS) and overall survival (OS) in hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2) negative metastatic breast cancer. We aimed to explore the relationship between metabolic tumor volume (MTV), total lesion glycolysis (TLG), and PFS/OS in these patients.

Methods

MTV and TLG were measured from baseline 18 F-fluorodeoxyglucose (18-FDG) positron emission tomography/computed tomography (PET/CT) of 87 HR-positive/HER2-negative metastatic breast cancer patients and their effects on survival were analyzed using Kaplan-Meier methods.

Results

The median OS was 42.0 months for patients with MTV < 121.7 cm³ and 24.6 months with ≥ 121.7 cm3 (p = 0.001). The median OS was 40.3 months for patients with TLG < 732.4 g and 24.6 months with ≥ 732.4 g (p = 0.006). The median OS for patients with an ECOG score of 0 was 53.6 months, while for those with an ECOG score of 1–2, it was 26.4 months (p = 0.005). Age ≥ 60 years (HR = 5.11, p = 0.002) and ECOG score > 0 (HR = 3.38, p = 0.011) are independent predictors of PFS.

Conclusions

Baseline 18 F-FDG PET/CT may provide prognostic insights in HR+/HER2- metastatic breast cancer. High MTV and TLG are associated with poorer OS in univariate analyses but not in multivariable analyses. ECOG score > 0 and age ≥ 60 years are independent predictors of PFS.